Platinum induced hearing loss in children with cancer: the prospective study

Cover Page

Cite item

Full Text

Abstract

Platinum containing chemotherapy regimens are widely used in the treatment of pediatric cancer. The irreversible bilateral sensoneural hearing loss is associated with cisplatin and carboplatin. The aim of our study was to evaluate risk factors and frequency of platinum-induced ototoxicity in children. 113 children were eligible in our study. All patients had normal hearing before the start of therapy. Bilateral sensoneural hearing loss was revealed in 25.7% of children. Younger age (before 5 y.o.), preceding cranial radiotherapy, treatment with carboplatin and cisplatin, cumulative dose of cisplatin more than 300 mg/m2 increased the risk of hearing loss.

About the authors

M. B. Belogurova

Saint-Petersburg State Pediatric Medical University;
Pediatric Tumors «Clinical Scientific and Practical Centre of Oncology»

Author for correspondence.
Email: deton.hospital31@inbox.ru
ORCID iD: 0000-0002-7471-7181

Margarita B. Belogurova, MD, PhD, Head of Department of Oncology, Pediatric Oncology and Radiotherapy 

Head of Department of Chemotherapy and Composite Treatment 

197758, St. Petersburg, Leningradskaya St., Pesochny 68 A

Russian Federation

E. S. Garbaruk

Saint-Petersburg State Pediatric Medical University

ORCID iD: 0000-0002-9535-6063
Russian Federation

N. V. Subora

Pediatric Tumors «Clinical Scientific and Practical Centre of Oncology»

ORCID iD: 0000-0001-9153-3803
Russian Federation

P. V. Pavlov

Saint-Petersburg State Pediatric Medical University

ORCID iD: 0000-0002-4626-201X
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Belogurova M.B., Garbaruk E.S., Subora N.V., Pavlov P.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.